JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB312511

Alexa Fluor® 568 Anti-TPD52 抗体 [EPR14220]

Alexa Fluor® 568 Anti-TPD52 antibody [EPR14220]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal TPD52 antibody - conjugated to Alexa Fluor® 568.

別名を表示する

Tumor protein D52, Protein N8, TPD52

関連する標識済み抗体及び組成の異なる製品 (10)

  • Unconjugated

    Anti-TPD52 antibody [EPR14220]

  • 578 PE

    PE Anti-TPD52 antibody [EPR14220]

  • 660 APC

    APC Anti-TPD52 antibody [EPR14220]

  • HRP

    HRP Anti-TPD52 antibody [EPR14220]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-TPD52 antibody [EPR14220]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-TPD52 antibody [EPR14220]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-TPD52 antibody [EPR14220]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-TPD52 antibody [EPR14220]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-TPD52 antibody [EPR14220]

  • Carrier free

    Anti-TPD52 antibody [EPR14220] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR14220

アイソタイプ

IgG

標識

Alexa Fluor® 568

励起波長/蛍光波長

Ex: 578nm, Em: 603nm

キャリアフリー

No

アプリケーション

Target Binding Affinity, Antibody Labelling

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

特異性

Based on immunogen sequence analysis, ab182578 recognizes 4 isoforms with the predicted MWs of 24KDa, 20KDa, 26 KDa and 22KDa, respectively.

style
left-column
style
left-column

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

style
left-column

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The Tumor Protein D52 (TPD52) is a 224 amino acid protein also known as PrLZ or D52-like protein 1 with a mass of approximately 23 kDa. TPD52 features prominently in the regulation of cell proliferation and vesicle trafficking. It is expressed in a wide range of tissues with significant expression levels in the pancreas prostate and various cancers. TPD52 associates with other members of the D52 family proteins forming homo- or heterodimers that play a part in its function.
Biological function summary

TPD52 is involved in cellular processes like growth apoptosis and exocytosis. It often forms part of protein complexes assisting in intracellular signaling pathways and vesicular transport mechanisms. The ability of TPD52 to interface with other proteins such as 14-3-3 or annexins provides it with diverse functionality. Moreover its involvement in regulating secretory pathways underlines its importance in different cell types particularly those with high secretion activity.

Pathways

TPD52 integrates into the MAPK and calcium signaling pathways. The MAPK pathway which includes key proteins like ERK1/2 involves TPD52 in processes affecting cell growth and differentiation. TPD52 can act upstream or downstream of MAPK components indicating its dynamic role in the pathway. Similarly in calcium signaling TPD52 interacts with annexins which position it within calcium-dependent exocytotic events and cellular responses dependent on Ca2+ dynamics.

TPD52 shows an association with cancers such as prostate and breast cancer. In breast cancer its overexpression correlates with rapid tumor growth and decreased patient survival rates. TPD52's link to the protein AKT suggests a role in oncogenic pathways where AKT promotes cell survival and growth. Similarly in prostate cancer altered expression levels of TPD52 may enhance tumorigenic potential and aggressiveness establishing TPD52 as a potential therapeutic target for cancer treatments.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

See full target information Tumor protein D52
style
left-column
style
left-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。
style
left-column
style
right-column

関連製品

Select an associated product type
Alternative Version
Primary Antibodies

AB250629

Anti-TPD52 antibody [EPR14220] - BSA and Azide free

primary-antibodies

tpd52-antibody-epr14220-bsa-and-azide-free-ab250629

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com